For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Related Articles Read More >
Q&A: Owkin’s five-year Sanofi deal bets on ‘purpose-built’ AI agents
Genetically modified hookworms could produce and deliver therapeutics within a host
Five costly mistakes when scaling spray drying from lab to commercial production
